Beating the Clock in T-cell Acute Lymphoblastic Leukemia.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 28007775.
- Also identified by DOI 10.1158/1078-0432.CCR-16-2825.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
CDK4/6 inhibition was synergistic with dexamethasone and everolimus but antagonistic with conventional chemotherapy in T-cell acute lymphoblastic leukemia (T-ALL) preclinical models. Cyclin-dependent kinase inhibition in combination with glucocorticoids and mTOR inhibition offers a unique therapeutic opportunity in T-ALL. <i>Clin Cancer Res; 23(4); 873-5. ©2016 AACR</i><i>See related article by Pikman et al., p. 1012</i>.
Medical subject headings
- Drug Resistance, Neoplasm
- Drug Synergism
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma